SRA1
Reactivity: Human
WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
ELISA: 1/10000
Restrictions
For Research Use only
Format
Liquid
Buffer
Ascitic fluid containing 0.03 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Chooniedass-Kothari, Hamedani, Troup, Hubé, Leygue: "The steroid receptor RNA activator protein is expressed in breast tumor tissues." in: International journal of cancer. Journal international du cancer, Vol. 118, Issue 4, pp. 1054-9, (2006) (PubMed).
Chooniedass-Kothari, Emberley, Hamedani, Troup, Wang, Czosnek, Hube, Mutawe, Watson, Leygue: "The steroid receptor RNA activator is the first functional RNA encoding a protein." in: FEBS letters, Vol. 566, Issue 1-3, pp. 43-7, (2004) (PubMed).
Lanz, Chua, Barron, Söder, DeMayo, OMalley: "Steroid receptor RNA activator stimulates proliferation as well as apoptosis in vivo." in: Molecular and cellular biology, Vol. 23, Issue 20, pp. 7163-76, (2003) (PubMed).
Steroid receptor RNA activator 1 (SRA), with 237-amino acid protein (about 27 kDa), belongs to the growing family of functional non-coding RNAs. SRA was originally described as the first functional noncoding RNA able to specifically coactivate the activity of steroid receptors. Specifically, SRA exists as both an RNA transcript that forms a complex with steroid receptor coactivator-1 and as a stably expressed protein. Its expression is strongly up-regulated in many human tumors of the breast, uterus, and ovary, suggesting a potential role in pathogenesis. Although coactivation of steroid-dependent transcription by SRA is accompanied by a proliferative response, overexpression is not in itself sufficient to induce turmorigenesis.